Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBoothwyn Pharmacy, LLC was cited for producing adulterated drug products, specifically sterile GLP-1 injectables compounded under insanitary conditions that created contamination and health risks in violation of federal manufacturing standards. During a May-June 2025 inspection, FDA investigators identified serious deficiencies in the pharmacy's drug production practices, including failure to maintain adequate sterility assurances and quality controls. The company voluntarily recalled all affected drug products with out-of-specification results in July 2025 and ceased GLP-1 sterile product production, though it notified FDA of plans to resume such manufacturing in August 2025.